VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design
Broadly neutralizing antibodies (bnAbs) are potential therapeutic molecules and valuable
tools for studying conserved viral targets for vaccine and drug design. Interestingly, antibody …
tools for studying conserved viral targets for vaccine and drug design. Interestingly, antibody …
Hepatitis C virus vaccine: challenges and prospects
The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a
global problem despite advances in antiviral therapeutics. Current treatments fail to prevent …
global problem despite advances in antiviral therapeutics. Current treatments fail to prevent …
Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies
P Pushparaj, A Nicoletto, DJ Sheward, H Das… - Immunity, 2023 - cell.com
The human immunoglobulin heavy-chain (IGH) locus is exceptionally polymorphic, with high
levels of allelic and structural variation. Thus, germline IGH genotypes are personal, which …
levels of allelic and structural variation. Thus, germline IGH genotypes are personal, which …
Structural insights into hepatitis C virus receptor binding and entry
A Kumar, RA Hossain, SA Yost, W Bu, Y Wang… - Nature, 2021 - nature.com
Hepatitis C virus (HCV) infection is a causal agent of chronic liver disease, cirrhosis and
hepatocellular carcinoma in humans, and afflicts more than 70 million people worldwide …
hepatocellular carcinoma in humans, and afflicts more than 70 million people worldwide …
Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate
Hepatitis C virus (HCV) infection affects approximately 58 million people and causes~
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …
Structure of the hepatitis C virus E1E2 glycoprotein complex
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis, and
hepatocellular carcinoma in humans and afflicts more than 58 million people worldwide. The …
hepatocellular carcinoma in humans and afflicts more than 58 million people worldwide. The …
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies
MC Metcalf, BM Janus, R Yin, R Wang… - Nature …, 2023 - nature.com
Hepatitis C virus (HCV) is a major global health burden as the leading causative agent of
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …
The hepatitis C virus envelope protein complex is a dimer of heterodimers
EH Augestad, C Holmboe Olesen, C Grønberg… - Nature, 2024 - nature.com
Fifty-eight million individuals worldwide are affected by chronic hepatitis C virus (HCV)
infection, a primary driver of liver cancer for which no vaccine is available. The HCV …
infection, a primary driver of liver cancer for which no vaccine is available. The HCV …
Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization
T Weber, J Potthoff, S Bizu, M Labuhn, L Dold… - Immunity, 2022 - cell.com
The high genetic diversity of hepatitis C virus (HCV) complicates effective vaccine
development. We screened a cohort of 435 HCV-infected individuals and found that 2%–5 …
development. We screened a cohort of 435 HCV-infected individuals and found that 2%–5 …
Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance
The early appearance of broadly neutralizing antibodies (bNAbs) in serum is associated
with spontaneous hepatitis C virus (HCV) clearance, but to date, the majority of bNAbs have …
with spontaneous hepatitis C virus (HCV) clearance, but to date, the majority of bNAbs have …